Heartland Financial USA, Inc. ("HTLF") Reports Quarterly Results as of March 31, 2024
April 29, 2024 07:30 ET
|
Heartland Financial USA, Inc.
First Quarter Highlights •Quarterly net income available to common stockholders of $49.7 million or $1.16 per common share•Adjusted earnings available to common stockholders of $52.4 million or $1.22...
Dragonfly Energy to Report First Quarter 2024 Financial and Operational Results on May 14, 2024
April 29, 2024 07:30 ET
|
Dragonfly Energy Holdings Corp.
Dragonfly Energy to release Q1 2024 financial and operational results on May 14, 2024, after market close, followed by an earnings call at 5pm ET.
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
April 29, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX:...
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
April 29, 2024 07:00 ET
|
Aquestive Therapeutics, Inc.
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg,...
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
April 29, 2024 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2024 financial results on Thursday, May 2, 2024 after the markets...
MoneyHero Group Reports Fourth Quarter and Full Year 2023 Results
April 29, 2024 07:00 ET
|
MoneyHero Limited
MoneyHero Group Reports Fourth Quarter and Full Year 2023 Results
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
April 29, 2024 07:00 ET
|
Prime Medicine, Inc.
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Arqit announces collaboration to deliver out-of-the-box post-quantum cryptography solutions
April 29, 2024 07:00 ET
|
Arqit
LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, today announced the creation of the World’s First Quantum-Safe, 1.89...
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
April 29, 2024 07:00 ET
|
Allarity Therapeutics, Inc.
Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments,...